Last reviewed · How we verify

NCT03924024

rTMS for Orthopaedic Trauma Patients

Withdrawn NA Last updated 9 May 2022
What this trial tests

NA trial testing Accelerated intermittent theta burst treatment in Orthopaedic Trauma. Withdrawn.

Timeline
1 August 2019
Primary endpoint
1 February 2021
1 February 2021

Quick facts

Lead sponsorStanford University
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 August 2019
Primary completion1 February 2021
Estimated completion1 February 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 18 to 65, any sex, with Orthopaedic Trauma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for orthopaedic trauma patients. In this open label study, all participants will receive accelerated theta-burst stimulation. This study will examine whether symptoms of psychiatric distress and opioid use in orthopaedic trauma patients can be mitigated with rTMS to improve post-injury recovery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults.
    Brown R, Cherian K, Jones K, Wickham R, et al · · 2024 · cited 6× · PMID 39092744 · DOI 10.1002/14651858.cd015040.pub2

Verify or expand the search:

Other recruiting trials for Orthopaedic Trauma

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03924024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing